Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 22, 2013New Data Presented In Late-Breaking Clinical Trial Session At EuroPCR Demonstrated Successful Deployment Of The Lotus™ Valve In The First 60 Patients With Minimal Paravalvular Regurgitation At 30 Days
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE:...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to...
-
May 15, 2013Study Evaluates Clinical Outcomes of Self-Expanding Metal Stents as a Bridge to Surgery
The first patient has been enrolled in a clinical investigation evaluating the use of the Boston Scientific Corporation (NYSE: BSX) WallFlex® Biliary...
-
May 10, 2013Industry-Leading Battery Life Reduces the Frequency of Replacement Surgery
New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization...
-
May 10, 2013Company Offers Mapping System with IntellaMap Orion™ Mapping Catheter in Effort to Significantly Enhance Physician Treatment Options
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation...
-
May 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left...
-
May 8, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2013 Healthcare Conference on May 15 in Las...
-
May 6, 2013
Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi™ XP Ablation Catheter for the...
-
May 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions...
-
Apr 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.761 billion and adjusted earnings per share of $0.16 for the first quarter ended March...
-
Apr 24, 2013Earth Week Celebration Focuses on 3,900-Panel Project at the Company’s International Distribution Center in Quincy
Natick, Mass. (April 24, 2013)—Boston Scientific Corporation (NYSE:BSX) celebrates Earth Week by inaugurating a 3,900-panel rooftop solar installation atop the company’s international...
-
Apr 15, 2013Innovative Device Quickly Anchors Leads and Catheters
Natick, Mass. (April 15, 2013) – Boston Scientific Corporation (NYSE: BSX) has acquired the fiXate™ Tissue Band and is launching the product in the United States. The fiXate Tissue Band is...
-
Apr 15, 2013
The first patient in the United States has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation ImageReady™ MR...
-
Apr 12, 2013World's First and Only System with Illumina 3D™ Software and 32 Contacts is Designed to Provide Pain Relief to a Broad Spectrum of Chronic Pain Patients
Boston Scientific Corporation (NYSE: BSX) has received approval by the U.S. Food and Drug Administration and is beginning a limited launch of the...
-
Apr 10, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2013 on...
-
Mar 21, 2013Results Revealed at CIT 2013
Platinum china trial demonstrates positive outcomes for the BOSTON SCIENTIFIC PROMUS ELEMENT™ STENT Results Revealed at CIT 2013 Beijing (March 21, 2013) – Boston Scientific Corporation...
-
Mar 13, 2013Deadly but Preventable Cancer is a Focus During Colorectal Cancer Awareness Month
NATICK, Mass., March 13, 2013 -- Boston Scientific Corporation (NYSE: BSX) is supporting several public education initiatives throughout the month of March to highlight the prevalence and...
-
Mar 10, 2013Separate Study Demonstrates PROMUS Element Stent has Significantly Less Vessel Straightening than the Xience V® Stent
Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and...
-
Mar 9, 2013WATCHMAN® Device Continues to Demonstrate Positive Clinical Outcomes for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at...
-
Mar 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The...
-
Mar 6, 2013First Presentation of the Preliminary Results of All Three Co-Primary Endpoints to be Revealed During The American College of Cardiology 2013 Annual Scientific Sessions
The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the...
-
Mar 6, 2013New Tool Available to Assist in the Treatment of Peripheral Arterial Disease
Boston Scientific Corporation (NYSE: BSX) has begun the launch of its 0.035" and 0.018" Rubicon™ Support Catheter in the United States. The device...